Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Blood Vessel

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    305 result(s) found for: Blood Vessel. Displaying page 1 of 16.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-003383-12 Sponsor Protocol Number: CLN-PRO-V005 Start Date*: 2021-07-05
    Sponsor Name:Humacyte, Inc.
    Full Title: A Phase 2 Study for the Evaluation of Safety and Efficacy of Humacyte’s Human Acellular Vessel for Vascular Replacement or Reconstruction in Patients with Life or Limb-threatening Vascular Trauma
    Medical condition: Vascular Replacement or Reconstruction in Patients with Life or Limb-threatening Vascular Trauma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022117 - Injury, poisoning and procedural complications 10047080 Vascular injury PT
    23.1 10022117 - Injury, poisoning and procedural complications 10022117 Injury, poisoning and procedural complications SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-002329-27 Sponsor Protocol Number: ETLAS-2 Start Date*: 2020-12-10
    Sponsor Name:Herlev Gentofte Hospital
    Full Title: Improving cerebral blood flow and cognition in patient with cerebral small vessel disease. The ETLAS-2 Trial.
    Medical condition: Cerebral small vessel disease and stroke.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10070879 Cerebral small vessel ischemic disease LLT
    22.1 10029205 - Nervous system disorders 10076994 Lacunar stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000896-26 Sponsor Protocol Number: ETLAS Start Date*: 2016-05-19
    Sponsor Name:Herlev Gentofte Hospital
    Full Title: Effect of Tadalafil on cerebral large arteries in stroke patients.
    Medical condition: Stroke and small vessel disease.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10070879 Cerebral small vessel ischemic disease LLT
    19.0 10029205 - Nervous system disorders 10076994 Lacunar stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-000171-15 Sponsor Protocol Number: IMT-MRI-Trial-2006 Start Date*: 2007-01-17
    Sponsor Name:University Hospital of Ulm
    Full Title: Randomized, placebo-controlled, double-blinded study evaluating the effects of Pioglitazone on intima-media-thickness (IMT) of the carotid arteries measured by MRI in non-diabetic patients with con...
    Medical condition: Male or female non-diabetic patients at an age between 30 and 79 years (inclusive) with a proven vascular disease defined as arteriosclerosis confirmed by presence of CAD, PAD or carotid plaques.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001235-20 Sponsor Protocol Number: 14.0189 Start Date*: 2015-06-05
    Sponsor Name:St George's University of London
    Full Title: Perfusion by Arterial Spin labelling following Single dose Tadalafil In Small vessel disease
    Medical condition: PARTICIPANTS WITH EVIDENCE OF CEREBRAL SMALL VESSEL DISEASE
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-005363-33 Sponsor Protocol Number: ESR-14-10048 Start Date*: 2015-04-16
    Sponsor Name:VU university medical center
    Full Title: Reducing Micro Vascular dysfunction In revascularized STEMI patients by off-target properties of ticagrelor
    Medical condition: ST elevation myocardial infarction (STEMI)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002730-11 Sponsor Protocol Number: A091031 Start Date*: 2007-11-30
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: Magnetic resonance (MR) angiography with a blood pool contrast medium.
    Medical condition: Abnormalities of the major venous system.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047184 Vein disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-005447-25 Sponsor Protocol Number: INTIMA Start Date*: 2013-02-22
    Sponsor Name:Academic Medical Center Amsterdam, department of Internal Medicine
    Full Title: The use of Rienso, an ultrasmall superparamagnetic particle of iron-oxide, as a MRI contrast agent to image inflammation in the atherosclerotic plaque
    Medical condition: Atherosclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004866 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004606-26 Sponsor Protocol Number: OBF-13 Start Date*: 2014-04-07
    Sponsor Name:Med. Uni. Wien, Klinik f. Innere Med. I
    Full Title: Exploratory study investigating ocular blood flow in colorectal cancer patients before and after treatment with anti-angiogenic therapy
    Medical condition: metastatic colorectal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019096-29 Sponsor Protocol Number: 2009CV08 Start Date*: 2011-02-15
    Sponsor Name:University of Dundee [...]
    1. University of Dundee
    2. NHS Tayside
    Full Title: The effects of oral vitamin D supplementation on cardiovascular disease risk in patients with Myalgic Encephalomyelitis /Chronic Fatigue Syndrome.
    Medical condition: Randomised, placebo controlled, parallel group, double blinded study to investigate if oral supplementation of vitamin D will improve vascular function and metabolic and inflammatory parameters in ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-005445-32 Sponsor Protocol Number: LA-II-02 Start Date*: 2016-06-24
    Sponsor Name:BIOrest, Ltd.
    Full Title: The BLADE-PCI Trial (PHASE IIB LIPOSOMAL ALENDRONATE STUDY): Biorest Liposomal Alendronate Administration for Diabetic Patients Undergoing Drug-Eluting Stent Percutaneous Coronary Intervention
    Medical condition: PCI (percutaneous coronary intervention) for angina, silent ischemia or non-STEMI in patients with diabetes mellitus.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004860 10012654 Diabetic complications cardiovascular HLT
    18.1 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-016855-23 Sponsor Protocol Number: CD09/9088 Start Date*: 2010-08-20
    Sponsor Name:University of Leeds
    Full Title: Targeting systemic inflammation to improve endothelial function in obesity
    Medical condition: Healthy volunteer trial in obese subjects (body mass index 30 or greater) in which the IMP will be used to reduce inflammation by inhibiting tumour necrosis factor(TNF)-α in order to assess the eff...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003998-28 Sponsor Protocol Number: CER-001-CLIN-003 Start Date*: 2012-01-24
    Sponsor Name:Cerenis Therapeutics
    Full Title: Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-Label Study of the Effects of CER-001 on Plaque Volume in Subjects with Homozygous Familial Hypercholesterolemia (HoFH)
    Medical condition: homozygous familial hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    15.0 10027433 - Metabolism and nutrition disorders 10020604 Hypercholesterolemia LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022308-34 Sponsor Protocol Number: JW/IB/AG Start Date*: 2011-04-19
    Sponsor Name:Central Manchester Foundation Hospitals Trust
    Full Title: Eplerenone in Metabolic Syndrome: An investigation into the effects of Eplerenone on perivascular adipose tissue and small artery tone in obesity
    Medical condition: Obesity and Metabolic Syndrome (combination of obesity, hypertension, raised blood glucose and cholesterol abnormalities)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10027433 - Metabolism and nutrition disorders 10052066 Metabolic syndrome PT
    13.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002096-26 Sponsor Protocol Number: MV-3-2017 Start Date*: 2017-08-24
    Sponsor Name:Universitetsklinik for Nyresygdomme og Blodtryksforhøjelse, Regionshospitalet Holstebro; Hospitalsenheden Vest
    Full Title: Investigate the differences between treating Chronic Kidney Disease - Mineral and Bone Disorder with an iron-containing phosphate binder or a calcium-containing phosphate binder in dialysis patients.
    Medical condition: Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD), especially bone metabolism and blood vessel calcification
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10027425 Metabolic bone disorders HLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10078095 Chronic kidney disease-mineral and bone disorder PT
    20.0 100000004869 10012347 Dependence on renal dialysis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002448-25 Sponsor Protocol Number: MA3RSTrial Start Date*: 2012-10-02
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian Health Board
    Full Title: Magnetic Resonance Imaging Using Ultrasmall Superparamagnetic Particles of Iron Oxide in Patients Under Surveillance for Abdominal Aortic Aneurysms to Predict Rupture or Surgical Repair: the MA3RS ...
    Medical condition: Abdominal Aortic Aneurysm
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2010-018531-17 Sponsor Protocol Number: TRED012010 Start Date*: 2010-06-25
    Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust
    Full Title: Effect of Tredaptive on serum lipoproteins, lipoproteins metabolism, oxidative stress and HDL antioxidant function.
    Medical condition: Hypercholesterolaemia.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006447-40 Sponsor Protocol Number: CSPP100A2366 Start Date*: 2009-02-23
    Sponsor Name:Novartis Farmacéutica
    Full Title: Estudio multicéntrico, aleatorizado, doble ciego, con grupos paralelos y de 104 semanas de duración, para evaluar la eficacia de aliskiren en la progresión de la aterosclerosis en pacientes con enf...
    Medical condition: Progresión de la aterosclerosis en pacientes con enfermedad arterial coronaria
    Disease: Version SOC Term Classification Code Term Level
    9 10011076 Coronary artery atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) FR (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002920-10 Sponsor Protocol Number: TRE-1486--0105-I Start Date*: 2016-09-14
    Sponsor Name:Klinikum der Universitaet Muenchen AoeR
    Full Title: TREAT-SVDs: EffecTs of Amlodipine and other Blood PREssure Lowering Agents on Microvascular FuncTion in Small Vessel Diseases
    Medical condition: Cerebral small vessel disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NL (Ongoing) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-004583-22 Sponsor Protocol Number: 548.12 Start Date*: 2012-10-20
    Sponsor Name:OSPEDALE PEDIATRICO BAMBINO GESU' DI ROMA
    Full Title: Verification of the effectiveness of intravenous sildenafil compared to other pulmonary vasodilators used in the test vessel reactivity of pulmonary
    Medical condition: Subjects in children with congenital heart disease surgery or not, with echocardiographic signs of pulmonary hypertension followed at the Pediatric Cardiology Centre of the Mediterranean or reporte...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10047065 Vascular disorders SOC
    Population Age: In utero, Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 06 11:57:46 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA